Oxcarbazepine (Oxtellar XR) vs Oxcarbazepine (Trileptal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
Reported efficacy
Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)
Result source: NCT00908349
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00050934 · Phase 3 · completed
The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records no allocation or masking for this study; the publication reports a randomized, rater-blind, parallel-group design.
Reported efficacy
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline): Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. (met)
Result source: NCT00050934
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Oxcarbazepine (Oxtellar XR) | Oxcarbazepine (Trileptal) |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not posted · NCT00050934 |
| 50% responder rate | 50% vs 34%+16 vs placeboNCT007726031 other result
| —Not posted · NCT00050934 |
| Seizure freedom | —Not reported | —Not posted · NCT00050934 |
Seizure frequency, % change
- Oxcarbazepine (Oxtellar XR)
- —Not reported
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
50% responder rate
- Oxcarbazepine (Oxtellar XR)
- 50% vs 34%+16 vs placeboNCT00772603
1 other result
- 44% vs 34% NCT00772603
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
Seizure freedom
- Oxcarbazepine (Oxtellar XR)
- —Not reported
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Oxcarbazepine (Oxtellar XR): 4 of 4 rows · Oxcarbazepine (Trileptal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Oxcarbazepine (Oxtellar XR) | Oxcarbazepine (Trileptal) |
|---|---|---|
| Dropout rate | 42.3%2400 mg/daya NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results32.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 16.4% NCT00908349 · Phase 3 · monotherapy | 14.6%b NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 30.1%2400 mg/daya NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results14.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 4.7% NCT00908349 · Phase 3 · monotherapy | 12.5%b NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy — NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 8.1%2400 mg/daya NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results5.7%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 8.4% NCT00908349 · Phase 3 · monotherapy | 2.1%b NCT00975715 · Phase 2/3 · combination show 5 more results0%Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination 0%Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence 0%450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence 0% NCT01678976 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 2400 mg/daya dizziness 40.7% (placebo 14.9%) headache 15.4% (placebo 7.4%) vomiting 15.4% (placebo 9.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results1200 mg/day dizziness 19.7% (placebo 14.9%) somnolence 11.5% (placebo 9.1%) diplopia 9.8% (placebo 4.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 | b somnolence 42.6% (placebo 9.8%) nasopharyngitis 10.6% (placebo 17.6%) vomiting 10.6% (placebo 5.9%) NCT00975715 · Phase 2/3 · combination show 5 more resultssomnolence 75% dizziness 56.3% headache 50% NCT03695094 · Phase 1 · registry result, not featured evidence · combination somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy headache 100% dizziness 85.7% back pain 71.4% NCT00900237 · Phase 1 · registry result, not featured evidence 450 mg Bid dizziness 54.5% somnolence 54.5% frontal headache 18.2% NCT01679002 · Phase 1 · registry result, not featured evidence dizziness 23.1% headache 23.1% nodule subcutaneous 15.4% NCT01678976 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Oxcarbazepine (Oxtellar XR)
show 1 more result
show 1 more result
show 1 more result
Focal Onset Seizures
Shared mechanism: Voltage-gated sodium channel · full Focal Onset Seizures pipeline
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
Reported efficacy
PCH(T), ITT (Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline): PCH(T), ITT (Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline): 2400mg/Day SPN-804 -42.9 percentage of change (range -100 to 212.8) | 1200mg/Day SPN-804 -38.2 percentage of change (range -100 to 556.1) | Placebo -28.7 percentage of change (range -100 to 333.6) (mixed)
Result source: NCT00772603
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00975715 · Phase 2/3 · completed
The study randomized 48 participants to TRI476 and 51 to placebo and was double-blind. Its primary clinical endpoint was change in seizure frequency, but statistical significance was not reported, so the trial provides useful controlled evidence without clearly establishing that the primary endpoint was met.
No aligned efficacy figure on record for this race.
Results for Focal Onset Seizures
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Oxcarbazepine (Oxtellar XR): no structured comparison results are available for Focal Onset Seizures.
Available safety results
Oxcarbazepine (Trileptal)
| Dropout rate | 14.6% NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | 12.5% NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
| Serious AEs | 2.1% NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | somnolence 42.6% (placebo 9.8%) nasopharyngitis 10.6% (placebo 17.6%) vomiting 10.6% (placebo 5.9%) NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxcarbazepine (Oxtellar XR)'s landscape · Oxcarbazepine (Trileptal)'s landscape